

26/F, HKRI Centre One, HKRI Taikoo Hui
288 Shimen Road (No.1)
Shanghai 200041, P. R. China
T: (86-21) 5298-5488
F: (86-21) 5298-5492

20380 Town Center Lane, Suite 128
Cupertino, CA 95014, USA
T: +1 888 886 8168
F: +1 888 808 2168

September 11, 2025

GenFleet Therapeutics (Shanghai) Inc.
(勁方醫藥科技(上海)股份有限公司)
Floors 2-5, Building 8, 1206 Zhangjiang Road,
Pudong New Area 201203, Shanghai
China

CITIC Securities (Hong Kong) Limited
18/F, One Pacific Place
88 Queensway
Hong Kong
as the Sole Sponsor and

CLSA Limited
18/F, One Pacific Place
88 Queensway
Hong Kong
as the representative of Hong Kong underwriters listed in Schedule 2 to the Hong Kong Underwriting Agreement (as defined below) and the international underwriters listed in Schedule I to the International Underwriting Agreement (as defined below) (collectively, the “Underwriters”)

Re: GenFleet Therapeutics (Shanghai) Inc.(勁方醫藥科技(上海)股份有限公司)

Ladies and Gentlemen:

We are qualified lawyers of the People’s Republic of China (“PRC”, which do not include the laws of Hong Kong Special Administrative Region, the Macau Special Administrative Region and Taiwan) and qualified patent attorneys of the United States (“U.S.”) and as such are qualified to issue this opinion based on the intellectual property laws of the PRC and the U.S. GenFleet Therapeutics (Shanghai) Inc. (together with its subsidiaries, collectively referred to as the “Company”) has requested us to conduct a

Beijing Head Office
Tel: (86-10) 8519-1300
Fax: (86-10) 8519-1350

Shanghai Office
Tel: (86-21) 5298-5488
Fax: (86-21) 5298-5492

Guangzhou Office
Tel: (86-20) 2805-9088
Fax: (86-20) 2805-9099

Shenzhen Office
Tel: (86-755) 2939-5288
Fax: (86-755) 2939-5289

Hangzhou Office
Tel: (86-571) 2689-8188
Fax: (86-571) 2689-8199

Chengdu Office
Tel: (86-28) 6739-8000
Fax: (86-28) 6739-8001

Xi'an Office
Tel: (86-29) 8550-9666

Qingdao Office
Tel: (86-532) 6869-5000
Fax: (86-532) 6869-5010

Dalian Office
Tel: (86-411) 8250-7578
Fax: (86-411) 8250-7579

Haikou Office
Tel: (86-898) 3633-3401
Fax: (86-898) 3633-3402

Hong Kong Office
Tel: (852) 2167-0000
Fax: (852) 2167-0050

New York Office
Tel: (1-737) 215-8491
Fax: (1-737) 215-8491

Silicon Valley Office
Tel: (1-888) 886-8168
Fax: (1-888) 808-2168

Seattle Office
Tel: (1-425) 448-5090
Fax: (1-888) 808-2168

due diligence review on certain intellectual property matters regarding the Company. We are providing this opinion pursuant to Clause 2 of the Hong Kong Underwriting Agreement dated September 10, 2025 (the “Hong Kong Underwriting Agreement”) between the Company and the Hong Kong Underwriters and Section 8 of the International Underwriting Agreement dated on or around September 17, 2025 (the “International Underwriting Agreement”, together with the Hong Kong Underwriting Agreement, the “Underwriting Agreements”) between the Company and the International Underwriters, each in connection with the proposed initial public offering of the Company in the Hong Kong Stock Exchange (the “Offering”). We act as special intellectual property counsel to the Company as to the intellectual property laws in the PRC and U.S., and our representation has been limited to matters individually referred to us by the Company. There may be patent and related matters involving or impacting the Company of which we are unaware.

In connection with this opinion, we have reviewed the statements included in the Prospectus (the “Disclosure Documents”) related to the patents and patent applications listed in Appendix A attached hereto (the “Company Patents”), trademarks listed in Appendix B attached hereto, and domain name listed in Appendix C attached hereto (together with the Company Patents, referred to as the “Company Intellectual Property Rights”) and the license agreements listed in Appendix D attached hereto (the “License Agreements”, all of which are governed by the PRC laws except for the SELLAS Agreement which is governed by the laws of the New York State of the U.S.), which are made in the section titled “SUMMARY” under the headings of “INTELLECTUAL PROPERTY RIGHTS”, made in the section titled “RISK FACTORS” under the headings “RISKS RELATING TO OUR INTELLECTUAL PROPERTY RIGHTS”, made in the section titled “BUSINESS” under the headings “INTELLECTUAL PROPERTY”, and made in the section titled “Appendix IV Statutory and General Information” under the heading “Further Information about Our Business—Intellectual Property Rights” (collectively, the “Intellectual Property Statements”). Except with respect to the Intellectual Property Statements, we did not participate in the preparation of the Disclosure Documents, and we have not been consulted to advise on any other part of the Disclosure Documents. We have limited our review of the Disclosure Documents to the Intellectual Property Statements.

The purpose of our professional engagement was not to establish or confirm factual matters set forth in the Prospectus, and we have not undertaken any obligation to verify those factual matters. Accordingly, except to the extent of our opinions set forth in paragraphs A to J below, we are not passing upon and we assume no responsibility for the accuracy, completeness or fairness of the statements contained in or incorporated by reference into the Disclosure Documents.

Based on the foregoing and subject to the assumptions, qualifications, limitations and exceptions as stated in this opinion, we advise you that:

- A. Nothing has come to our attention causing us to believe that any of the Intellectual Property Statements contains any untrue statement of material fact or fails to state

any material fact necessary to make the statements therein not misleading, and, to our knowledge, all such statements are accurate and complete and present fairly the information therein.

- B. To our knowledge, the Company owns or otherwise possesses sufficient rights under all intellectual property rights that are currently employed by the Company in connection with their respective businesses, or that is necessary for the manufacture, importation, use, or sale of its product candidates as described in the Disclosure Documents. We have not become aware of any facts causing us to believe that the Company does not own or has not obtained licenses for, or other rights to use, the Company Intellectual Property Rights described as being owned or licensed or used by them as described in the Disclosure Documents.
- C. The Company owns or otherwise possesses sufficient rights under the License Agreements for the manufacture, importation, use, or sale of their product candidates as set forth in the License Agreements subject to terms, conditions and limitations set forth in the License Agreements.
- D. To our knowledge, the Company has not in respect of any patent received any notice of infringement of or conflict with any patent rights of others which, in either case, individually or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would have a material adverse effect on the Company.
- E. To our knowledge, there is no claim, action, suit or proceeding pending or threatened against the Company alleging that the Company has infringed, misappropriated or otherwise violated any intellectual property rights of any third party in the PRC or the U.S. We have not become aware of any facts causing us to believe that the current or planned development and commercialization of the Company's product candidates, as described in the Disclosure Documents, would infringe any issued patents of any third party that, in our opinion, are valid and enforceable. To our knowledge, the Company has not, in respect of any patent, received any notice of infringement of or conflict with any patent rights of others which, in either case, individually or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would have a material adverse effect on the Company.
- F. Except as described in the intellectual property due diligence report dated September 8, 2025, to our knowledge, no claim, action, suit or proceeding (including any interference, post grant reexamination, derivation, inter partes review, post grant review, opposition or other judicial or administrative proceeding) pertaining to the validity, enforceability or scope of any of the Company Intellectual Property Rights has been threatened or declared.
- G. To our knowledge, there are no liens, encumbrances or security interests against any Company Patents.

- H. To our knowledge, all applicable fees and surcharges and administrative procedures in relation to the maintenance of the Company Intellectual Property Rights have been duly and properly paid and proceeded.
- I. We have not become aware of any facts causing us to believe that the claims of the issued, unexpired patents included in the Company Patents are invalid or unenforceable under the laws of the PRC and the United States.
- J. We have reviewed the License Agreements listed under Appendix D. To our knowledge, each of the License Agreements governed by PRC laws listed in Appendix D has been duly authorized and executed by the Company, and upon the due authorization, execution and delivery by all other parties thereto, is valid, legally binding and enforceable against all parties thereunder in accordance with its terms.

The opinions expressed herein are also subject to the following assumptions, limitations, qualifications and exceptions:

- (a) As to matters of fact, we have assumed the authenticity and validity of all records furnished to us by the Company and the information and certificates from various public officials, and we have not made any independent investigation or verification of the authenticity and validity of such records, information and certificates.
- (b) Whenever our opinions herein are qualified by the phrase “to our knowledge”, or “known to us” or similar phrases, the relevant knowledge is limited to the current actual knowledge after due and careful inquiry of those attorneys presently in our firm who have performed substantive legal services for the Company in connection with this opinion.
- (c) Except for the issuance of a separate intellectual property due diligence report on September 8, 2025 and our investigation in connection therewith, and except for our discussions with the Company and our review of documents provided by the Company in connection with this Offering, we have not made any independent investigation with respect to the legal status of the Company Intellectual Property Rights, whether any of the Company Intellectual Property Rights covers the Company’s product candidates as described in the Disclosure Documents, whether the pending claims that cover the Company’s relevant product candidates in the patent applications of the Company Intellectual Property Rights are assured to be granted, and whether any third-party intellectual property rights constitute a hindrance for the manufacture, importation, use, or sale of the Company’s product candidates as described in the Disclosure Documents.
- (d) The opinions expressed herein represent our reasonable judgment as to the

matter of law addressed herein, based upon the facts presented, and are not, and shall not be construed as, a guarantee.

- (e) In acting as intellectual property counsel to the Company as to the intellectual property laws in the PRC and U.S., we have not been involved with the prosecution of the Company Intellectual Property Rights. Any opinions set forth in this opinion are limited to the patent laws of the People's Republic of China and the patent laws of the United States, to the extent that the same may apply to or govern such matters addressed herein.

This opinion is provided to the Company, the Sole Sponsor and CLSA Limited (in its capacity as the representative of the Underwriters under the Underwriting Agreements) and is solely for your benefit in connection with the Offering. This opinion may not be relied upon by you for any other purpose. This opinion may also not be provided to or relied upon by any other person or entity for any purpose, including, without limitation, any person or entity that acquires any securities of the Company from any of the Underwriters without our prior written consent, which we may withhold at our sole discretion. Notwithstanding these limitations, this opinion can properly be furnished to others (i) for the purpose of responding to requests to review this opinion by governmental, regulatory or judicial authorities (including the Hong Kong Stock Exchange, the Securities and Futures Commission of Hong Kong and the China Securities Regulatory Commission) having competent jurisdiction over you and (ii) in connection with the defense of any legal or regulatory proceeding or investigation arising out of the Offering, *provided* that JunHe LLP and Jun He Law Offices P.C. are given written notice in advance to the extent permitted by applicable laws.

This opinion is limited to the matters expressly set forth herein, and no opinion has been implied, or may be inferred, beyond the matters expressly stated.

This opinion is based on the law and facts as of the date hereof and we undertake no obligation or responsibility to update or supplement this opinion to reflect any facts, circumstances, or changes in the law that may later occur or come to our attention.

(Signature Page to Follow)

[This page is only for the purpose of the signature of IP Opinion prepared for the use of the Initial Public Offering of GenFleet Therapeutics (Shanghai) Inc. In the Hong Kong Stock Exchange]

Very truly yours,



Jun He Law Offices P.C.

Jun He Law Offices P.C.

APPENDIX A - PATENTS AND PATENT APPLICATIONS OWNED OR IN-LICENSED BY GENFLEET

(as of September 2, 2025)




Products	Name of Patent Family	Jurisdiction	Status	Filing Date	Grant Date	Patent Expiration Date	Type	Owner/Applicant	Inventor
GFH925	Substituted Heterocyclic Fused Cyclic Compound, Preparation Method Therefor and Pharmaceutical Use Thereof	China	Granted	2020-10-28	2022-8-5	2040-10-28	Invention	GENFLEET THERAPEUTICS (SHANGHAI) INC.; ZHEJIANG GENFLEET THERAPEUTICS CO., LTD.	Fusheng Zhou, Tao Jiang, Chonglan Lin, Lijian Cai, Wan He, Jiong Lan
		United States			2024-8-6				
		China	Pending	2020-10-28	-	-	Invention		
		United States			-	-			
GFH925	Polymorph of KRAS Inhibitor, Preparation Method Therefor, and Use Thereof	China, United States	Pending	2022-12-23	-	-	Invention	GENFLEET THERAPEUTICS (SHANGHAI) INC.; ZHEJIANG GENFLEET THERAPEUTICS CO., LTD.	Fusheng Zhou, Jinzhu Zhao, Yudong Cao, Lun Xiong, Rongzhen Shi, Jiong

									Xiangchao Liu, Mengting Meng, Fusheng Zhou, JingRong Li, Jiong Lan, Qiang Lu
GFH375	Pyrimidine-Fused Ring Compound, and Preparation Method Therefor and Use Thereof	China	Pending	2023-9- 25	-	-	Invention	GENFLEET THERAPEUTICS (SHANGHAI) INC.; ZHEJIANG GENFLEET THERAPEUTICS CO., LTD.	Tao Jiang, Fusheng Zhou, Tao Liang, Chonglan Lin, Lijian Cai, Zhubo Liu, Xiaoming Xu, Kai Ma, Leitao Zhang, Zhen Li, Jiong Lan

			China	Granted	2021-2-9	2024-2-9	2041-2-9	Invention	GENFLEET THERAPEUTICS (SHANGHAI) INC.; ZHEJIANG GENFLEET THERAPEUTICS CO., LTD.	Fusheng Zhou, Xiaoming Xu, Leitao Zhang, Xin Li, Lili Tang, Jiong Lan
GFH312	Dihydronaphthyrinone Compound, and Preparation Method Therefor and Medical Use Thereof		United States	Pending	2021-2-9	-	-			
GFH312	Crystal Form of RIPK1 Inhibitor, Acid Salt Thereof, and Crystal Form of Acid Salt Thereof		China, United States	Pending	2022-8-2	-	-	Invention	GENFLEET THERAPEUTICS (SHANGHAI) INC.; ZHEJIANG GENFLEET THERAPEUTICS CO., LTD.	Fusheng Zhou, Yuanzhi Tao, Jinzhu Zhao, Jiong Lan
GFH276	Macrocyclic Compounds, and Preparation Method Therefor and Use Thereof		PCT	Pending	2024-8-30	-	-	Invention	GENFLEET THERAPEUTICS (SHANGHAI) INC.	Jichen Zhao, Fusheng Zhou, Tao Liang, Yandong Lu; Tao Jiang; Chonglan Lin; Ling

									Peng; Jiong Lan; Qiang Lu	
GFH009	Inhibitor of Cyclin-Dependent Kinase CDK9	China	Granted	2017-4-19	2020-6-19	2037-4-19	Invention		GENFLEET THERAPEUTICS (SHANGHAI) INC.; ZHEJIANG GENFLEET THERAPEUTICS CO., LTD.	Gang Zhou
									GENFLEET THERAPEUTICS (SHANGHAI) INC.	
GFH018	Benzotriazole-Derived α And β -Unsaturated Amide Compound Used as TGF- β R1 Inhibitor	China	Granted	2017-6-8	2021-2-26	2037-6-8	Invention		GENFLEET THERAPEUTICS (SHANGHAI) INC.; ZHEJIANG GENFLEET THERAPEUTICS CO., LTD.	Fei Sun, Lifang Wu, Charles Z. Ding, Guoping Hu, Jian Li, Shuhui Chen, Jianyu Lu
									GENFLEET THERAPEUTICS (SHANGHAI) INC.	

APPENDIX B - TRADEMARKS OWNED BY GENFLEET
(as of September 2, 2025)

序号	商标图示	注册所 载司 法管 辖区	注册 号/ 申请 号	申请 日	注册 有效 期限	权利 人	类 号	核定 使用 商品/ 服务 内容
1		中国	51025814	2020-11-05	2021-08-07 至 2031-08-06	劲方医药科技（上海）股份有限公司	42	质量检测；生物化学研究和分析；化学研究服务；化学服务；生物医学研究服务；开发医药制剂和药品；抗体方面的研究和开发；生物学研究和分析；临床试验；生物技术研究
2		中国	65254924	2022-6-13	2023-04-07 至 2033-04-06	劲方医药科技（上海）股份有限公司	5	牙用研磨剂；宠物尿布
3		中国	72980546	2023-7-21	2024-05-21 至 2034-05-20	劲方医药科技（上海）股份有限公司	5	医用同位素；放射性药品；心电图电极用化学导体；医用气体

APPENDIX C - DOMAIN NAME OWNED BY GENFLEET

(as of September 2, 2025)

No.	Domain	Applicant	Registration Date	Expiry Date	ICP Registration No.	Approval Date
1	genfleet.com	劲方医药科技（上海）股份有限公司	2017-04-06	2027-04-06	沪 ICP 备 18006424 号-1	2024-10-31

APPENDIX D – LICENSE AGREEMENTS

1. A license and option agreement entered by and between GenFleet Therapeutics (Shanghai) Inc. (劲方医药科技（上海）有限公司¹ in Chinese) and Innovent Biologics, Inc. dated September 1, 2021; a supplemental agreement thereto entered by and among GenFleet Therapeutics (Shanghai) Inc., Innovent Biologics, Inc. and Innovent Biologics (Suzhou) Co., Ltd. (信达生物制药（苏州）有限公司 in Chinese); a supplementary agreement thereto by and among GenFleet Therapeutics (Shanghai) Inc., GenFleet Biologics (Shanghai) Inc. (劲方生物医药（上海）有限公司 in Chinese), Innovent Biologics, Inc., Innovent Biologics (Suzhou) Co., Ltd. and Innovent Biologics Technology Co., Ltd. (信达生物科技有限公司 in Chinese) dated January 11, 2024.
2. A technology transfer agreement entered by and between GenFleet Therapeutics (Shanghai) Inc. (劲方医药科技（上海）有限公司 in Chinese) and Shanghai Jionghuo Pharmaceutical Technology Co., Ltd. (上海炯烁医药科技有限公司 in Chinese) dated May 23, 2018; and an amendment thereto dated October 10, 2018.
3. A license agreement entered by and between SELLAS Life Sciences Group, Inc. and GenFleet Therapeutics (Shanghai) Inc. (劲方医药科技（上海）有限公司 in Chinese) dated March 31, 2022 (the “SELLAS Agreement”).
4. A co-development agreement by and between GenFleet Therapeutics (H.K.) Limited (健發藥業(香港)有限公司 in Chinese) and Wuxi APPTec (Shanghai) Co., Ltd. (上海药明康德新药开发有限公司 in Chinese) effective as of June 15, 2017; a supplementary agreement thereto by and among GenFleet Therapeutics (H.K.) Limited, Wuxi APPTec (Shanghai) Co., Ltd. and GenFleet Therapeutics (Shanghai) Inc. (劲方医药科技（上海）有限公司 in Chinese) effective as of September 24, 2017; and an intellectual property ownership agreement by and between GenFleet Therapeutics (Shanghai) Inc. and Medshine Discovery Inc. (南京明德新药研发股份有限公司 in Chinese) dated December 25, 2017.

¹ The Company's Chinese name has been changed to 劲方医药科技（上海）股份有限公司 since September 2024.